Your browser doesn't support javascript.
loading
Neutralization of the adaptor protein PAG by monoclonal antibody limits murine tumor growth.
Strazza, Marianne; Moore, Emily K; Adam, Kieran; Azoulay-Alfaguter, Inbar; Mor, Adam.
Afiliação
  • Strazza M; Columbia Center for Translational Immunology, Columbia University Medical Center, New York, NY 10032, USA.
  • Moore EK; Columbia Center for Translational Immunology, Columbia University Medical Center, New York, NY 10032, USA.
  • Adam K; Columbia Center for Translational Immunology, Columbia University Medical Center, New York, NY 10032, USA.
  • Azoulay-Alfaguter I; Perlmutter Cancer Center, New York University School of Medicine, New York, NY 10016, USA.
  • Mor A; Columbia Center for Translational Immunology, Columbia University Medical Center, New York, NY 10032, USA.
Mol Ther Methods Clin Dev ; 27: 380-390, 2022 Dec 08.
Article em En | MEDLINE | ID: mdl-36419471
The transmembrane adaptor phosphoprotein associated with glycosphingolipid-enriched microdomains 1 (PAG) is phosphorylated in T cells downstream of PD-1 signaling and contributes to the resulting functional inhibition of multiple cellular processes. Furthermore, PAG expression is negatively correlated with survival in multiple human tumors and is a driver of murine tumor growth and immune evasion. Here we develop an antibody that targets the extracellular domain of human PAG, with cross-reactivity to murine PAG. We demonstrate that this antibody binds to extracellular PAG on intact cells and affects T cell activation. Finally, we show that administration of anti-PAG monoclonal antibody in combination with anti-PD-1 antibody to mice bearing MC38 tumors limited tumor growth and enhanced T cell infiltration to tumors.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Mol Ther Methods Clin Dev Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos País de publicação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Mol Ther Methods Clin Dev Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos País de publicação: Estados Unidos